Clinical trials: Polypoidal Choroidal Vasculopathy (PCV)
Polypoidal Choroidal Vasculopathy
Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
To determine whether complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (PCV) with ranibizumab.
- Trial name
- NCT01271426
- Where
- Japan
- Volunteers
- 74 people
- Sponsor
- Nihon University
Polypoidal Choroidal Vasculopathy
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT03941587
- Testing
- Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- Where
- 2 sites in Singapore
- Volunteers
- 60 people
- Sponsor
- Singapore National Eye Centre
Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal…
- Trial name
- EVEREST II (NCT01846273)
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 41 sites in Hong Kong, Japan and 5 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a…
- Conditions
- Polypoidal Choroidal Vasculopathy, Choroidal Neovascularization, Age-Related Macular Degeneration
- Trial name
- NCT05662943
- Testing
- Intravitreal aflibercept injection
- Where
- South Korea
- Volunteers
- 135 people
- Sponsor
- Kim's Eye Hospital
Polypoidal Choroidal Vasculopathy
Initial Versus Delayed PDT Combination With Conbercept in PCV
To compare the initial versus delayed verteporfin photodynamic therapy (PDT) in combination with conbercept in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT02821520
- Testing
- conbercept, Initial PDT, Delayed PDT
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The Eye Hospital of Wenzhou Medical University
Neovascular (Wet) AMD
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
- Trial name
- NCT06550011
- Testing
- ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Avirmax Biopharma Inc
Neovascular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)
The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.
- Trial name
- RIVAL (NCT02092532)
- Testing
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
The goal of this clinical trial is to investigate the efficacy, durability, and safety of aflibercept 8 mg in treating Polypoidal Choroidal Vasculopathy (PCV) in Chinese naive patients.
- Trial name
- NCT07365371
- Testing
- Aflibercept Intravitreous Injection
- Where
- 20 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neovascular Macular Degeneration
Aflibercept in Polypoidal Choroidal Vasculopathy
To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration
- Trial name
- PLANET (NCT02120950)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 62 sites in Australia, Germany and 6 more
- Volunteers
- 333 people
- Sponsor
- Bayer
Polypoidal Choroidal Vasculopathy
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
To determine long-term outcomes, recurrence rates, and treatment needs in Polypoidal Choroidal Vasculopathy (PCV). Specifically, to describe the long-term outcomes, recurrence rates and treatment patterns PCV patients 5 years…
- Trial name
- NCT03929731
- Testing
- Indocyanine Green Angiography
- Where
- 3 sites in Singapore
- Volunteers
- 72 people
- Sponsor
- Singapore National Eye Centre
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Polypoidal Choroidal Vasculopathy
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
The primary objective of this study is to examine effects of fosbretabulin tromethamine (fosbretabulin) on PCV as reflected by a change from baseline in the number of polypoid lesions on indocyanine green angiography (ICGA).
- Trial name
- NCT01023295
- Testing
- fosbretabulin, Saline
- Where
- 5 sites in United States, Hong Kong and 3 more
- Volunteers
- 20 people
- Sponsor
- Mateon Therapeutics
Age Related Macular Degeneration
PDT Study for Exudative AMD With PCV
The purpose of this study is to evaluate and conduct an exploratory comparison of the efficacy and safety of indocyanine green angiography (ICGA) guided photodynamic therapy (PDT) and fluorescein angiography (FA) guided PDT for…
- Trial name
- NCT00331435
- Testing
- Ocular photodynamic therapy with verteporfin
- Where
- 17 sites in Japan
- Volunteers
- 113 people
- Sponsor
- Ophthalmic PDT Study Group
Polypoidal Choroidal Vasculopathy
Clinical Implication of Aflibercept in PCV Treatment in China
The purpose of this study is to evaluate the overall treatment characteristics and efficacy of Aflibercept in the treatment of PCV in China through a multicenter, observational, prospective-retrospective study.
- Trial name
- NCT05639660
- Testing
- non-interventional
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Macular Polypoidal Choroidal Vasculopathy (PCV)
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor…
- Trial name
- PROUD (NCT05666804)
- Testing
- Brolucizumab 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Polypoidal Choroidal Vasculopathy
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
The goal of this clinical trial is to assess the efficacy, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- MONDEGO (NCT06709339)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 31 sites in Italy, Portugal and 2 more
- Volunteers
- 120 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Polypoidal Choroidal Vasculopathy
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African descendants.
- Trial name
- NCT04707027
- Testing
- Aflibercept Injection (2 mg/0.05 ml), Defer treatment
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chiang Mai University
Polypoidal Choroidal Vasculopathy
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL (NCT00424710)
- Testing
- ranibizumab intravitreal injection
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hawaii Pacific Health
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with…
- Trial name
- PCV (NCT00674323)
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 5 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis
Symtomatic Macular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.
- Trial name
- NCT02860858
- Testing
- Intravitreous aflibercept injection
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand